• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    5/20/24 1:28:52 PM ET
    $AKAN
    $AKTS
    $BCAN
    $BNED
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKAN alert in real time by email

    Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) fell sharply during Monday's session after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share.

    Virios Therapeutics shares dipped 47.6% to $0.1850 on Monday.

    Here are some other stocks moving in today’s mid-day session.

    Gainers

    • MultiMetaVerse Holdings Limited (NASDAQ:MMV) shares jumped 224% to $2.01. MultiMetaVerse Holdings signed a non-binding term sheet to acquire 100% of Bowong Technology (Shenzhen) Co., Ltd. and its subsidiaries.
    • GT Biopharma, Inc. (NASDAQ:GTBP) rose 146% to $7.64. GT Biopharma, last week, posted a narrower-than-expected quarterly loss.
    • Tantech Holdings Ltd (NASDAQ:TANH) jumped 89.8% to $1.2501.
    • Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) shares gained 62.1% to $1.6701. Faraday Future Intelligent Electric is scheduled to report its fourth quarter and full year 2023 results after the closing bell on Tuesday, May 28.
    • CN Energy Group. Inc. (NASDAQ:CNEY) surged 58% to $1.0501.
    • Scorpius Holdings, Inc. (NASDAQ:SCPX) gained 57.8% to $0.1635. Scorpius, last week, announced closing of public offering.
    • NKGen Biotech, Inc. (NASDAQ:NKGN) rose 46% to $1.6250 after the company’s SNK01 NK Cell Therapy was cleared to begin a Phase 2 trial in Alzheimer’s disease.
    • Bruush Oral Care Inc. (NASDAQ:BRSH) jumped 41% to $0.1658.
    • Rekor Systems, Inc. (NASDAQ:REKR) gained 36% to $1.80 after the company announced a partnership with MS2.
    • MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) gained 34.3% to $0.8866 after the company said it has advanced new preclinical studies using Ketamir-2 towards clinical development.
    • Scilex Holding Company (NASDAQ:SCLX) gained 34% to $1.21.
    • Hims & Hers Health, Inc. (NYSE:HIMS) rose 30.5% to $19.01 after the company announced the addition of GLP-1 injections to its weight loss portfolio.
    • BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) surged 29.5% to $1.4250.
    • Cheetah Mobile Inc. (NYSE:CMCM) gained 24.3% to $5.70.
    • Concord Medical Services Holdings Limited (NYSE:CCM) jumped 23% to $0.6188.
    • Wix.com Ltd. (NASDAQ:WIX) rose 21.6% to $164.94 as the company posted upbeat results for its first quarter and raised its 2024 forecast on Monday.
    • Sintx Technologies, Inc. (NASDAQ:SINT) shares rose 21.1% to $0.1029 after dipping over 39% on Friday.
    • Sutro Biopharma, Inc. (NASDAQ:STRO) climbed 17.6% to $4.7150.
    • PTC Therapeutics, Inc. (NASDAQ:PTCT) jumped 17.2% to $38.78 after the company announced the European Commission has returned the Translarna opinion to the CHMP for re-evaluation.
    • Cue Health Inc. (NASDAQ:HLTH) gained 17.1% to $0.1128 after dipping around 18% on Friday. Cue Health, last week, announced that it voluntarily and temporarily paused sales and distribution of its EUA COVID-19 Test Cartridge.
    • NextDecade Corporation (NASDAQ:NEXT) climbed 16% to $8.10 after ADNOC announced it secured an equity position and LNG offtake agreement in NextDecade’s Rio Grande LNG project.
    • NuScale Power Corporation (NYSE:SMR) rose 15.5% to $7.29.
    • VinFast Auto Ltd. (NASDAQ:VFS) gained 15% to $5.61.
    • Crown ElectroKinetics Corp. (NASDAQ:CRKN) shares rose 14.8% to $0.1964 after falling around 29% on Friday.
    • Tellurian Inc. (NASDAQ:TELL) gained 14% to $0.5870.
    • Shineco, Inc. (NASDAQ:SISI) shares climbed 10.2% to $1.09 after jumping 19% on Friday. Shineco recently announced that its subsidiaries Fuzhou Medashan Biotechnology and Kaifeng Yixi Biotechnology invented a new natural active water-soluble product.
    • Independent Bank Group, Inc. (NASDAQ:IBTX) gained 8.5% to $47.69 after SouthState announced it will acquire the company.
    • Doximity, Inc. (NYSE:DOCS) surged 5.1% to $29.46.

    Losers

    • Akoustis Technologies, Inc. (NASDAQ:AKTS) fell 53.8% to $0.1647 after Qorvo won a jury verdict against the company in a trade secret misappropriation and patent infringement case.
    • Cheetah Net Supply Chain Service Inc. (NASDAQ:CTNT) declined 48% to $5.61.
    • FLJ Group Limited (NASDAQ:FLJ) shares fell 44.5% to $0.86 after surging 224% on Friday.
    • Jaguar Health, Inc (NASDAQ:JAGX) fell 39.8% to $0.1557 after the company announced a 1-for-60 reverse stock split.
    • Fangdd Network Group Ltd. (NASDAQ:DUO) declined 38% to $1.04.
    • Jeffs’ Brands Ltd (NASDAQ:JFBR) shares declined 35.8% to $0.4189 after jumping 109% on Friday.
    • DermTech, Inc. (NASDAQ:DMTK) fell 33.8% to $0.3302.
    • CervoMed Inc. (NASDAQ:CRVO) declined 25.3% to $17.99. CervoMed named William Elder as Chief Financial Officer, effective June 1.
    • Barnes & Noble Education, Inc. (NYSE:BNED) dipped 22.6% to $0.3482.
    • Akanda Corp. (NASDAQ:AKAN) shares fell 22.3% to $0.1339 following a 30% surge on Friday.
    • iPower Inc. (NASDAQ:IPW) shares fell 20.8% to $2.29 after jumping 98% on Friday. iPower, last week, reported better-than-expected third-quarter financial results.
    • Nature’s Miracle Holding Inc. (NASDAQ:NMHI) declined 19.9% to $0.5396. Nature’s Miracle mutually agreed to terminate plan to merge with Agrify Corp.
    • Li Auto Inc. (NASDAQ:LI) fell 12.6% to $21.74 after the company reported worse-than-expected first-quarter results and issued second-quarter guidance.
    • GameStop Corp. (NYSE:GME) declined 10% to $19.99.
    • Oklo Inc. (NYSE:OKLO) fell 8.6% to $8.23.
    • IGM Biosciences, Inc. (NASDAQ:IGMS) declined 8.2% to $8.46.
    • Cemtrex, Inc. (NASDAQ:CETX) shares fell 7.6% to $0.45 after climbing 49% on Friday. Cemtrex, last week, posted a wider quarterly loss.
    • The Beauty Health Company (NASDAQ:SKIN) declined 5.8% to $2.58.
    • Inovio Pharmaceuticals, Inc. (NASDAQ:INO) fell 5.6% to $11.33.
    • ATRenew Inc. (NASDAQ:RERE) shares fell 4.3% to $2.71 after reporting weak quarterly earnings.

    Now Read This: How To Earn $500 A Month From Lowe’s Stock Ahead Of Q1 Earnings Report

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $AKTS
    $BCAN
    $BNED

    CompanyDatePrice TargetRatingAnalyst
    Li Auto Inc.
    $LI
    3/17/2026$19.00Buy → Neutral
    Goldman
    Wix.com Ltd.
    $WIX
    3/12/2026$98.00Neutral
    Piper Sandler
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$24.00Sell → Neutral
    Citigroup
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    Wix.com Ltd.
    $WIX
    3/9/2026$90.00Outperform → Neutral
    Robert W. Baird
    Hims & Hers Health Inc.
    $HIMS
    3/9/2026$30.00Hold → Buy
    Needham
    Aktis Oncology Inc.
    $AKTS
    3/9/2026$30.00Buy
    H.C. Wainwright
    NextDecade Corporation
    $NEXT
    3/5/2026$7.00 → $6.00Hold
    TD Cowen
    More analyst ratings

    $AKAN
    $AKTS
    $BCAN
    $BNED
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $AKAN
    $AKTS
    $BCAN
    $BNED
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKAN
    $AKTS
    $BCAN
    $BNED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Luo Jun

    3 - Fangdd Network Group Ltd. (0001750593) (Issuer)

    3/23/26 8:38:49 PM ET
    $DUO
    Real Estate
    Finance

    SEC Form 3 filed by new insider Li Yang Ly

    3 - Fangdd Network Group Ltd. (0001750593) (Issuer)

    3/23/26 8:36:40 PM ET
    $DUO
    Real Estate
    Finance

    SEC Form 3 filed by new insider Peng Senlin

    3 - Fangdd Network Group Ltd. (0001750593) (Issuer)

    3/23/26 8:34:31 PM ET
    $DUO
    Real Estate
    Finance

    $AKAN
    $AKTS
    $BCAN
    $BNED
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

    – Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned dual-payload program targeting PTK7, STRO-227, accelerating IND submission to 2026 – – Astellas-partnered iADC dual-payload program enters the clinic; patient dosing underway – – Cash, cash equivalents and marketable securities as of December 31, 2025 of $141.4 million, excluding proceeds from the recent capital raise of approximately $110 million which extended cash runway into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma,

    3/23/26 4:05:00 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™

    Pooled analyses in patients with moderate Alzheimer's show dose-related cognitive benefit and signs of durability. 100% of patients remained stable or improved, with 50% improving from moderate to mild cognitive function. Exploratory plasma GFAP correlations are consistent with observed clinical outcomes. Findings support further evaluation of troculeucel's immunomodulatory approach in the ongoing Phase 2 trial. SANTA ANA, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeuti

    3/23/26 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKAN
    $AKTS
    $BCAN
    $BNED
    SEC Filings

    View All

    SEC Form S-3 filed by Sutro Biopharma Inc.

    S-3 - SUTRO BIOPHARMA, INC. (0001382101) (Filer)

    3/23/26 5:23:05 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Sutro Biopharma Inc.

    S-8 - SUTRO BIOPHARMA, INC. (0001382101) (Filer)

    3/23/26 5:10:25 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Sutro Biopharma Inc.

    10-K - SUTRO BIOPHARMA, INC. (0001382101) (Filer)

    3/23/26 4:44:40 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKAN
    $AKTS
    $BCAN
    $BNED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Li Auto downgraded by Goldman with a new price target

    Goldman downgraded Li Auto from Buy to Neutral and set a new price target of $19.00

    3/17/26 7:56:17 AM ET
    $LI
    Auto Manufacturing
    Industrials

    Piper Sandler resumed coverage on Wix.com with a new price target

    Piper Sandler resumed coverage of Wix.com with a rating of Neutral and set a new price target of $98.00

    3/12/26 8:55:45 AM ET
    $WIX
    Computer Software: Programming Data Processing
    Technology

    Hims & Hers Health upgraded by Citigroup with a new price target

    Citigroup upgraded Hims & Hers Health from Sell to Neutral and set a new price target of $24.00

    3/10/26 8:37:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $AKAN
    $AKTS
    $BCAN
    $BNED
    Financials

    Live finance-specific insights

    View All

    Cheetah Mobile To Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 24, 2026

    BEIJING, March 19, 2026 /PRNewswire/ -- Cheetah Mobile Inc. ("Cheetah Mobile" or the "Company") (NYSE: CMCM), a China-based IT company with a commitment to AI innovation, today announced that it will report its financial results for the fourth quarter and fiscal year 2025 before the U.S. market opens on Tuesday, March 24, 2026. The earnings release will be available on the Company's investor relations website at http://ir.cmcm.com. Cheetah Mobile's management will hold an earnings conference call at 7:00 AM on Tuesday, March 24, 2026, U.S. Eastern Time (7:00 PM on Tuesday, March 24, 2026, Beijing Time/Hong Kong Time).Participants may access the call by dialing the following numbers:Main Line

    3/19/26 9:00:00 AM ET
    $CMCM
    Computer Software: Prepackaged Software
    Technology

    Rekor Systems Secures Landmark Patent for "Incident-Based" Data Retention, Replacing Outdated ALPR and Vehicle Dragnets with Privacy-First Intelligent Storage

    COLUMBIA, Md., March 18, 2026 (GLOBE NEWSWIRE) -- Rekor Systems, Inc. (NASDAQ:REKR), ("Rekor" or the "Company"), a leader in developing and implementing cutting-edge roadway intelligence systems, announced today that the United States Patent and Trademark Office has granted a new patent for an innovative method of dynamically storing automatic license plate ("ALPR") and vehicle recognition data based on the severity of suspected criminal activity. The patent also covers PII data retention policies developed with input from both public safety agencies and the communities they serve. Public safety agencies have traditionally stored automated license plate recognition data with fixed retenti

    3/18/26 7:30:00 AM ET
    $REKR
    Telecommunications Equipment
    Telecommunications

    Oklo Publishes Full-Year 2025 Financial Results and Business Update

    Oklo Inc. (NYSE:OKLO) ("Oklo" or "the Company"), an advanced nuclear technology company, today published its financial results and business update for the quarter and year ended December 31, 2025. Oklo will host a conference call today, March 17, 2026, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. Jacob DeWitte, Co-Founder and Chief Executive Officer, and Craig Bealmear, Chief Financial Officer, will speak on the call. A webcast of the call can be accessed by visiting the Events & Presentations section of the Company's investor relations website. An archive of the webcast will be available shortly after the conclusion of the event and will be available for 12 months. About Oklo

    3/17/26 4:00:00 PM ET
    $OKLO
    Electric Utilities: Central
    Utilities

    $AKAN
    $AKTS
    $BCAN
    $BNED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fangdd Network Group Ltd.

    SC 13G - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:26:40 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by Fangdd Network Group Ltd.

    SC 13G/A - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:24:27 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by Cheetah Net Supply Chain Service Inc.

    SC 13G/A - CHEETAH NET SUPPLY CHAIN SERVICE INC. (0001951667) (Subject)

    12/12/24 4:29:36 PM ET
    $CTNT
    Motor Vehicles
    Consumer Discretionary

    $AKAN
    $AKTS
    $BCAN
    $BNED
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Barnes & Noble Education Reports Fiscal Third Quarter 2026 Financial Results

    BNC First Day Program Revenue Increases 32.1% Net Income of $6.7 Million and Adjusted EBITDA of $23.6 Million Company to Commence Dividend Program in First Quarter of Fiscal 2027 Virtual Investor Day Scheduled for June 25, 2026 FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Barnes & Noble Education, Inc. (NYSE:BNED), ("Barnes & Noble Education," "BNED," "the Company," "we," "us," "our"), a leading solutions provider for the education industry, today reported financial results for the fiscal third quarter ended January 31, 2026. Virtual Investor Day Barnes & Noble Education has scheduled a virtual investor day for June 25, 2026. Management will provide an overview of the Com

    3/10/26 4:15:00 PM ET
    $BNED
    Other Specialty Stores
    Consumer Discretionary